Cargando…

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases

Neoadjuvant immunochemotherapy has attracted much attention as a treatment for locally advanced non-small-cell lung cancer. However, there is scarce evidence of the safety and efficacy of camrelizumab as neoadjuvant in lung cancer. Here, we present three patients who were diagnosed with IIIA squamou...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin, Xia, Chunqiu, Liu, Minghui, Liu, Jinghao, Dong, Ming, Zhao, Honglin, Xu, Song, Wang, Dan, Wei, Sen, Song, Zuoqing, Chen, Gang, Liu, Hongyu, Chen, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514096/
https://www.ncbi.nlm.nih.gov/pubmed/36176413
http://dx.doi.org/10.3389/fonc.2022.843116
_version_ 1784798204707995648
author Li, Xin
Xia, Chunqiu
Liu, Minghui
Liu, Jinghao
Dong, Ming
Zhao, Honglin
Xu, Song
Wang, Dan
Wei, Sen
Song, Zuoqing
Chen, Gang
Liu, Hongyu
Chen, Jun
author_facet Li, Xin
Xia, Chunqiu
Liu, Minghui
Liu, Jinghao
Dong, Ming
Zhao, Honglin
Xu, Song
Wang, Dan
Wei, Sen
Song, Zuoqing
Chen, Gang
Liu, Hongyu
Chen, Jun
author_sort Li, Xin
collection PubMed
description Neoadjuvant immunochemotherapy has attracted much attention as a treatment for locally advanced non-small-cell lung cancer. However, there is scarce evidence of the safety and efficacy of camrelizumab as neoadjuvant in lung cancer. Here, we present three patients who were diagnosed with IIIA squamous non-small-cell lung cancer from September to December in 2020 and received two cycles of neoadjuvant camrelizumab plus nab-paclitaxel and nedaplatin, followed by surgical resection. All three patients had a reduction in the tumor size on CT image and not delayed planned surgery. We did not observe grade 3 or 4 adverse events. Two of the three patients achieved a major pathological response (MPR), including one complete tumor regression of the primary lung tumor. Multiplex fluorescent immunohistochemistry revealed that CD8+ T cells, FoxP3+ regulatory T cells, and PD-L1 expression on immune cells in the surgical specimen were much higher than in the pretreatment biopsy sample in patients with MPR. This was not observed in the patient without MPR. Camrelizumab plus chemotherapy could potentially be a neoadjuvant regimen for resectable IIIA squamous non-small-cell lung cancer, with a high MPR proportion, and did not compromise surgical procedure. Our findings should be validated in a future randomized clinical trial.
format Online
Article
Text
id pubmed-9514096
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95140962022-09-28 Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases Li, Xin Xia, Chunqiu Liu, Minghui Liu, Jinghao Dong, Ming Zhao, Honglin Xu, Song Wang, Dan Wei, Sen Song, Zuoqing Chen, Gang Liu, Hongyu Chen, Jun Front Oncol Oncology Neoadjuvant immunochemotherapy has attracted much attention as a treatment for locally advanced non-small-cell lung cancer. However, there is scarce evidence of the safety and efficacy of camrelizumab as neoadjuvant in lung cancer. Here, we present three patients who were diagnosed with IIIA squamous non-small-cell lung cancer from September to December in 2020 and received two cycles of neoadjuvant camrelizumab plus nab-paclitaxel and nedaplatin, followed by surgical resection. All three patients had a reduction in the tumor size on CT image and not delayed planned surgery. We did not observe grade 3 or 4 adverse events. Two of the three patients achieved a major pathological response (MPR), including one complete tumor regression of the primary lung tumor. Multiplex fluorescent immunohistochemistry revealed that CD8+ T cells, FoxP3+ regulatory T cells, and PD-L1 expression on immune cells in the surgical specimen were much higher than in the pretreatment biopsy sample in patients with MPR. This was not observed in the patient without MPR. Camrelizumab plus chemotherapy could potentially be a neoadjuvant regimen for resectable IIIA squamous non-small-cell lung cancer, with a high MPR proportion, and did not compromise surgical procedure. Our findings should be validated in a future randomized clinical trial. Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9514096/ /pubmed/36176413 http://dx.doi.org/10.3389/fonc.2022.843116 Text en Copyright © 2022 Li, Xia, Liu, Liu, Dong, Zhao, Xu, Wang, Wei, Song, Chen, Liu and Chen https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Xin
Xia, Chunqiu
Liu, Minghui
Liu, Jinghao
Dong, Ming
Zhao, Honglin
Xu, Song
Wang, Dan
Wei, Sen
Song, Zuoqing
Chen, Gang
Liu, Hongyu
Chen, Jun
Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
title Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
title_full Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
title_fullStr Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
title_full_unstemmed Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
title_short Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
title_sort neoadjuvant camrelizumab and chemotherapy in patients with resectable stage iiia squamous non-small-cell lung cancer: clinical experience of three cases
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514096/
https://www.ncbi.nlm.nih.gov/pubmed/36176413
http://dx.doi.org/10.3389/fonc.2022.843116
work_keys_str_mv AT lixin neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases
AT xiachunqiu neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases
AT liuminghui neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases
AT liujinghao neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases
AT dongming neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases
AT zhaohonglin neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases
AT xusong neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases
AT wangdan neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases
AT weisen neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases
AT songzuoqing neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases
AT chengang neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases
AT liuhongyu neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases
AT chenjun neoadjuvantcamrelizumabandchemotherapyinpatientswithresectablestageiiiasquamousnonsmallcelllungcancerclinicalexperienceofthreecases